Onconetix, Inc. Files S-1/A Amendment
Ticker: ONCO · Form: S-1/A · Filed: Jun 25, 2024 · CIK: 1782107
| Field | Detail |
|---|---|
| Company | Onconetix, INC. (ONCO) |
| Form Type | S-1/A |
| Filed Date | Jun 25, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.00001, $1.09, $1.3625, $2.546, $0.153 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceuticals
TL;DR
Onconetix (fka Blue Water Biotech) filed S-1/A amendment. Public offering incoming?
AI Summary
Onconetix, Inc. filed an S-1/A amendment on June 24, 2024, for its registration statement. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio.
Why It Matters
This filing indicates Onconetix, Inc. is actively pursuing a public offering or other securities-related actions, which could impact its capital structure and future operations.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate events like IPOs or secondary offerings, which carry inherent market and execution risks.
Key Numbers
- 333-277066 — SEC File Number (Identifies the specific registration statement)
- 20240624 — Filing Date (Date the amendment was submitted)
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former Company Name
- Blue Water Vaccines Inc. (company) — Former Company Name
- 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio (location) — Principal Executive Offices
- Karina M. Fedasz (person) — Interim Officer
FAQ
What is the purpose of this S-1/A filing?
This is Amendment No. 3 to the Form S-1 Registration Statement, indicating updates or revisions to the original filing.
What were Onconetix, Inc.'s previous names?
The company was formerly known as Blue Water Biotech, Inc. (name change on 20230424) and Blue Water Vaccines Inc. (name change on 20190710).
Where is Onconetix, Inc. headquartered?
The company's principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.
What is Onconetix, Inc.'s industry?
Onconetix, Inc. operates in the Pharmaceutical Preparations sector, with a Standard Industrial Classification code of 2834.
When was the company incorporated?
Onconetix, Inc. was incorporated in Delaware.
Filing Stats: 4,508 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-06-24 20:28:01
Key Financial Figures
- $0.00001 — e "Company," or "Onconetix"), par value $0.00001 per share (the "Common Stock"), by the
- $1.09 — ducement PIOs have an exercise price of $1.09 per share and will expire five years fr
- $1.3625 — ducement PIOs have an exercise price of $1.3625 per share and will expire five years fr
- $2.546 — he Sabby PIOs have an exercise price of $2.546 per share and will expire five years fr
- $0.153 — daq Capital Market on June 18, 2024 was $0.153 per share. We recommend that you obtain
Filing Documents
- ea0208249-s1a3_onconetix.htm (S-1/A) — 4319KB
- ea020824901ex23-1_onconetix.htm (EX-23.1) — 2KB
- ea020824901ex23-2_onconetix.htm (EX-23.2) — 2KB
- ea020824901ex23-3_onconetix.htm (EX-23.3) — 5KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 25KB
- image_003.jpg (GRAPHIC) — 17KB
- image_004.jpg (GRAPHIC) — 14KB
- image_005.jpg (GRAPHIC) — 186KB
- image_006.jpg (GRAPHIC) — 152KB
- ex23-3_001.jpg (GRAPHIC) — 6KB
- 0001213900-24-055360.txt ( ) — 17601KB
- onco-20240331.xsd (EX-101.SCH) — 141KB
- onco-20240331_cal.xml (EX-101.CAL) — 130KB
- onco-20240331_def.xml (EX-101.DEF) — 806KB
- onco-20240331_lab.xml (EX-101.LAB) — 1217KB
- onco-20240331_pre.xml (EX-101.PRE) — 826KB
- ea0208249-s1a3_onconetix_htm.xml (XML) — 1772KB
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 103 PROTEOMEDIX
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 119 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 148 DESCRIPTION OF CAPITAL STOCK 149 SELLING STOCKHOLDERS 153 PLAN OF DISTRIBUTION 155 EXPERTS 156 LEGAL MATTERS 156 WHERE YOU CAN FIND MORE INFORMATION 156 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using a "shelf" registration process for the delayed or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix, Inc. and our Common Stock. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of up to 7,828,812 shares of our Common Stock from time to time through any means described in the section entitled " Plan of Distribution ." We will not receive any proceeds from the sale of shares of Common Stock to be offered by the Selling Stockholders pursuant to this prospectus. However, we will pay the expenses, other than underwriting discounts and commissions, associated with the sale of shares pursuant to this prospectus. We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions " Where You Can Find More Information " and " Incorporation of Certain Information by Reference ." No offer of these securities will be made in any jurisdiction where the offer is not permitted. You should rely only on the information contained in or incorporated